You are here: Industry Insights > Market News > Whitepaper: VIVAPUR® MCG – a powerful stabiliser for nasal sprays

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Whitepaper: VIVAPUR® MCG – a powerful stabiliser for nasal sprays

europeanpharmaceuticalreviewJune 17, 2019

Tag: nasal , Spray , JRS , VIVAPUR MCG

Favorites

JRS Pharma present VIVAPUR MCG and outline the benefits of its formulation for application in nasal sprays.

Dispersible cellulose is a multifunctional and commonly used stabiliser for nasal sprays containing APIs such as Fluticasone, Budesonide, Beclometasone, Triamcinolone Acetonide or Oxymetazoline Hydrochloride.

The gel network keeps drug particles suspended in the main reservoir of the delivery device. During pumping, the gel becomes fluid in the delivery device and enables an eased spraying and efficient and standardised atomisation.

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content,

please email: Julia.Zhang@ubmsinoexpo.com

Previous:Sapropterin Dihydrochloride Tablets 100 mg

Next:Eurofins BioPharma Product Testing

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Whitepaper: VIVAPUR® MCG – a powerful stabiliser for nasal sprays | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

PET plastic spray bottle xinjitai BP142-50

Trisodium Phosphate Anhydrous Centrifugal Spray Dryer

Topical Spray pump xinjitai Mechanical spray pump Plastic Topical Fine Mist SprayerXH113-24-410

PE plastic spray bottle spray bottle Pharmaceutical PE bottlesBP048-60

PE plastic spray bottle spray bottle Pharmaceutical xinjitai PE bottlesYY021-30

HDPE spray bottle PE plastic spray bottle fine mist spray bottle, nasal spray bottle throat spray bo

PE plastic spray bottle spray bottle Pharmaceutical PE bottlesYY010-12

YPG series pressure spray granulation dryer

Topical Sprayer Medicine Spray Pump xinjitai Fine Mist SprayerXH196-18-415

Oral Spray Pump, Throat Spray Pump, Screw on Closures, with HDPE bottles

Whitepaper: VIVAPUR® MCG – a powerful stabiliser for nasal sprays

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>